| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| John M Kane, Christoph U Correll, Donald C Goff, Brian Kirkpatrick, Stephen R Marder, Estelle Vester-Blokland, Wei Sun, William H Carson, Andrei Pikalov, Sheila Assunção-Talbot. A multicenter, randomized, double-blind, placebo-controlled, 16-week study of adjunctive aripiprazole for schizophrenia or schizoaffective disorder inadequately treated with quetiapine or risperidone monotherapy. The Journal of clinical psychiatry. vol 70. issue 10. 2009-11-23. PMID:19906340. |
this study investigated aripiprazole adjunctive to risperidone or quetiapine for treating schizophrenia and schizoaffective disorder. |
2009-11-23 |
2023-08-12 |
Not clear |
| Nina Segnitz, Andrea Schmitt, Peter J Gebicke-Härter, Mathias Zin. Differential expression of glutamate transporter genes after chronic oral treatment with aripiprazole in rats. Neurochemistry international. vol 55. issue 7. 2009-11-17. PMID:19524631. |
these transcriptional effects exerted by aripiprazole may counteract a glutamatergic deficit state and strengthen the neurotransmission of glutamate with positive consequences on cognitive and negative symptoms of schizophrenia. |
2009-11-17 |
2023-08-12 |
rat |
| Huang-Chi Lin, Mian-Yoon Chong, Yu Lee, Wei-Chiang Yeh, Pao-Yen Li. Switching of antipsychotics to aripiprazole in the treatment of schizophrenia. Chang Gung medical journal. vol 32. issue 4. 2009-11-16. PMID:19664347. |
switching of antipsychotics to aripiprazole in the treatment of schizophrenia. |
2009-11-16 |
2023-08-12 |
Not clear |
| Shubhra Mace, David Taylo. Aripiprazole: dose-response relationship in schizophrenia and schizoaffective disorder. CNS drugs. vol 23. issue 9. 2009-11-09. PMID:19689167. |
aripiprazole: dose-response relationship in schizophrenia and schizoaffective disorder. |
2009-11-09 |
2023-08-12 |
Not clear |
| Shubhra Mace, David Taylo. Aripiprazole: dose-response relationship in schizophrenia and schizoaffective disorder. CNS drugs. vol 23. issue 9. 2009-11-09. PMID:19689167. |
aripiprazole is an atypical antipsychotic that has been shown to be more effective than placebo and at least as effective as haloperidol and risperidone in the treatment of schizophrenia and schizoaffective disorder. |
2009-11-09 |
2023-08-12 |
Not clear |
| Shubhra Mace, David Taylo. Aripiprazole: dose-response relationship in schizophrenia and schizoaffective disorder. CNS drugs. vol 23. issue 9. 2009-11-09. PMID:19689167. |
in this review we examined the efficacy data from short-term studies of aripiprazole in relapsed schizophrenia or schizoaffective disorder, in order to establish a dose-response relationship for aripiprazole. |
2009-11-09 |
2023-08-12 |
Not clear |
| Sung-Wan Kim, Il-Seon Shin, Jae-Min Kim, Tak Youn, Su-Jin Yang, Michael Y Hwang, Jin-Sang Yoo. The 5-HT2 receptor profiles of antipsychotics in the pathogenesis of obsessive-compulsive symptoms in schizophrenia. Clinical neuropharmacology. vol 32. issue 4. 2009-10-08. PMID:19644229. |
we report the development of de novo obsession induced by sequential treatment with risperidone, aripiprazole, and ziprasidone, which have an antagonist effect on serotonin 5-ht(2a) receptors in a patient with schizophrenia. |
2009-10-08 |
2023-08-12 |
Not clear |
| Hiroyoshi Takeuchi, Hiroyuki Uchida, Takefumi Suzuki, Koichiro Watanabe, Haruo Kashim. Predictors of clinical worsening after a switch to aripiprazole in patients with schizophrenia: a 1-year naturalistic follow-up study. Journal of clinical psychopharmacology. vol 29. issue 4. 2009-09-17. PMID:19593185. |
predictors of clinical worsening after a switch to aripiprazole in patients with schizophrenia: a 1-year naturalistic follow-up study. |
2009-09-17 |
2023-08-12 |
Not clear |
| Chang Yoon Kim, Seockhoon Chung, Joon-Noh Lee, Jun Soo Kwon, Do Hoon Kim, Chul Eung Kim, Bumseok Jeong, Yang-Whan Jeon, Min-Soo Lee, Tae-Youn Jun, Hee-Yeon Jun. A 12-week, naturalistic switch study of the efficacy and tolerability of aripiprazole in stable outpatients with schizophrenia or schizoaffective disorder. International clinical psychopharmacology. vol 24. issue 4. 2009-09-15. PMID:19451828. |
a 12-week, naturalistic switch study of the efficacy and tolerability of aripiprazole in stable outpatients with schizophrenia or schizoaffective disorder. |
2009-09-15 |
2023-08-12 |
Not clear |
| Chang Yoon Kim, Seockhoon Chung, Joon-Noh Lee, Jun Soo Kwon, Do Hoon Kim, Chul Eung Kim, Bumseok Jeong, Yang-Whan Jeon, Min-Soo Lee, Tae-Youn Jun, Hee-Yeon Jun. A 12-week, naturalistic switch study of the efficacy and tolerability of aripiprazole in stable outpatients with schizophrenia or schizoaffective disorder. International clinical psychopharmacology. vol 24. issue 4. 2009-09-15. PMID:19451828. |
the objectives of this 12-week multicenter open-label switching study were to evaluate the overall clinical efficacy, safety, and tolerability of aripiprazole in stable patients with schizophrenia or schizoaffective disorder, and to assess, in a naturalistic setting, whether such patients experience symptom worsening when switched from d2 receptor antagonists to aripiprazole (a d2 receptor partial agonist). |
2009-09-15 |
2023-08-12 |
Not clear |
| Chang Yoon Kim, Seockhoon Chung, Joon-Noh Lee, Jun Soo Kwon, Do Hoon Kim, Chul Eung Kim, Bumseok Jeong, Yang-Whan Jeon, Min-Soo Lee, Tae-Youn Jun, Hee-Yeon Jun. A 12-week, naturalistic switch study of the efficacy and tolerability of aripiprazole in stable outpatients with schizophrenia or schizoaffective disorder. International clinical psychopharmacology. vol 24. issue 4. 2009-09-15. PMID:19451828. |
patients with schizophrenia or schizoaffective disorder in a symptomatically stable state were randomized to aripiprazole or standard-of-care antipsychotics. |
2009-09-15 |
2023-08-12 |
Not clear |
| Chang Yoon Kim, Seockhoon Chung, Joon-Noh Lee, Jun Soo Kwon, Do Hoon Kim, Chul Eung Kim, Bumseok Jeong, Yang-Whan Jeon, Min-Soo Lee, Tae-Youn Jun, Hee-Yeon Jun. A 12-week, naturalistic switch study of the efficacy and tolerability of aripiprazole in stable outpatients with schizophrenia or schizoaffective disorder. International clinical psychopharmacology. vol 24. issue 4. 2009-09-15. PMID:19451828. |
in the naturalistic setting, symptomatically stable outpatients with schizophrenia who were switched to aripiprazole showed clinically meaningful treatment benefits. |
2009-09-15 |
2023-08-12 |
Not clear |
| C J Bachmann, D Lehr, F M Theisen, M Preis. Aripiprazole as an adjunct to clozapine therapy in adolescents with early-onset schizophrenia: a retrospective chart review. Pharmacopsychiatry. vol 42. issue 4. 2009-09-15. PMID:19585394. |
aripiprazole as an adjunct to clozapine therapy in adolescents with early-onset schizophrenia: a retrospective chart review. |
2009-09-15 |
2023-08-12 |
Not clear |
| Tracy S Cummings, Douglas L Noords. Treatment of catatonic schizophrenia with lorazepam and aripiprazole. Schizophrenia research. vol 112. issue 1-3. 2009-09-03. PMID:19411162. |
treatment of catatonic schizophrenia with lorazepam and aripiprazole. |
2009-09-03 |
2023-08-12 |
Not clear |
| David C Henderson, Xiaoduo Fan, Paul M Copeland, Bikash Sharma, Christina P Borba, Ryan Boxill, Oliver Freudenreich, Corinne Cather, A Eden Evins, Donald C Gof. Aripiprazole added to overweight and obese olanzapine-treated schizophrenia patients. Journal of clinical psychopharmacology. vol 29. issue 2. 2009-08-18. PMID:19512978. |
aripiprazole added to overweight and obese olanzapine-treated schizophrenia patients. |
2009-08-18 |
2023-08-12 |
human |
| David C Henderson, Xiaoduo Fan, Paul M Copeland, Bikash Sharma, Christina P Borba, Ryan Boxill, Oliver Freudenreich, Corinne Cather, A Eden Evins, Donald C Gof. Aripiprazole added to overweight and obese olanzapine-treated schizophrenia patients. Journal of clinical psychopharmacology. vol 29. issue 2. 2009-08-18. PMID:19512978. |
we report the results of a 10-week placebo-controlled, double-blind crossover study that examined 15 mg/d aripiprazole's effects on weight, lipids, glucose metabolism, and psychopathology in overweight and obese schizophrenia and schizoaffective disorder subjects treated with a stable dose of olanzapine. |
2009-08-18 |
2023-08-12 |
human |
| Hitoshi Takahashi, Takashi Oshimo, Jun Ishigook. Efficacy and tolerability of aripiprazole in first-episode drug-naive patients with schizophrenia: an open-label trial. Clinical neuropharmacology. vol 32. issue 3. 2009-08-10. PMID:19483480. |
efficacy and tolerability of aripiprazole in first-episode drug-naive patients with schizophrenia: an open-label trial. |
2009-08-10 |
2023-08-12 |
Not clear |
| Hitoshi Takahashi, Takashi Oshimo, Jun Ishigook. Efficacy and tolerability of aripiprazole in first-episode drug-naive patients with schizophrenia: an open-label trial. Clinical neuropharmacology. vol 32. issue 3. 2009-08-10. PMID:19483480. |
the purpose of this study is to investigate the safety and efficacy of aripiprazole in first-episode drug-naive patients with schizophrenia. |
2009-08-10 |
2023-08-12 |
Not clear |
| F Bergmann, A Zacher, A Nass, R Urban, C Werner, T Spevakné-Göröcs, M Kungel, M Ebrecht, S Model. Psychosocial functioning in patients with schizophrenia treated with aripiprazole - an office-based real-world setting. Results from the German post-marketing surveillance study. Pharmacopsychiatry. vol 42. issue 3. 2009-08-06. PMID:19452378. |
psychosocial functioning in patients with schizophrenia treated with aripiprazole - an office-based real-world setting. |
2009-08-06 |
2023-08-12 |
Not clear |
| V Ryckmans, J P Kahn, S Modell, C Werner, R D McQuade, W Kerselaers, J Lissens, R Sanche. Switching to aripiprazole in outpatients with schizophrenia experiencing insufficient efficacy and/or safety/tolerability issues with risperidone: a randomized, multicentre, open-label study. Pharmacopsychiatry. vol 42. issue 3. 2009-08-06. PMID:19452380. |
switching to aripiprazole in outpatients with schizophrenia experiencing insufficient efficacy and/or safety/tolerability issues with risperidone: a randomized, multicentre, open-label study. |
2009-08-06 |
2023-08-12 |
Not clear |